Evaluating the impact of geriatric assessments on treatment for older AML patients
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
This study is testing if a thorough health check for older adults with newly diagnosed acute myeloid leukemia can help doctors choose better treatments and improve their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05909501 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the physiologic age of newly diagnosed acute myeloid leukemia (AML) patients aged 50 and older, focusing on a holistic evaluation rather than chronological age alone. By measuring various health parameters at baseline, the study will analyze outcomes such as treatment toxicity, early mortality, remission rates, and long-term survival in patients receiving either intensive or non-intensive treatment. The findings will help inform new guidelines for treating older adults with AML.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed AML patients aged 50 years and older who are considering a new line of treatment.
Not a fit: Patients who are unable to understand the study or complete questionnaires independently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for older AML patients.
How similar studies have performed: While there is ongoing research in geriatric assessments in oncology, this specific approach to AML treatment in older adults is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy * New diagnosis being considered for new line of treatment * Age ≥ 50 years. * Performance status 0,1, and 2 Exclusion Criteria: * Inability to understand or unable to sign a written informed consent * Unable to fill out questionnaires on their own and/or do not have someone to help complete them
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Catherine Lai, MD — Abramson Cancer Center at Penn Medicine
- Study coordinator: Colleen Redlinger
- Email: colleen.redlinger@pennmedicine.upenn.edu
- Phone: 2152209693
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.